← Leaderboards
Heidi A Kay
Jericho Sciences, Llc
$1,570,144
Attributed
$3,717,195
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,717,195 · 5
By mechanism
R44$1,792,335 · 1
R43$1,603,997 · 3
R41$320,863 · 1
Top collaborators
- Rick B Meeker3 shared
- Diane L. Bolton2 shared
- Lola C Hudson2 shared
- Jay Rappaport2 shared
- Haitao Guo1 shared
- Avindra Nath1 shared
- Ned C Sacktor1 shared
- Jerry Thomas Thornthwaite1 shared
Others in their field
Top investigators on “Source”
- Richard A Gibbs · Baylor College Of Medicine$285,393,445
- David Heimbrook · Leidos Biomedical Research, Inc.$233,184,481
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- Jeffrey P Krischer · University Of South Florida$224,745,020
- Albert Lazzarini · California Institute Of Technology$202,317,285
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$155,571,437
Research focus
SourceVirusAffectAntiviral AgentsAnti-Retroviral AgentsSmall MoleculeHiv-1ViralInfectionCellsFeline Immunodeficiency VirusPeripheral Blood Mononuclear CellClinical TrialsResponseLeadDoseNeuraxisHighly Active Antiretroviral TherapyAcquired Immunodeficiency SyndromeCytokineIn VitroIn VivoAids/Hiv ProblemHiv Infections
Grant awards (8)
Translational Development of a Small Molecule for the Treatment of HBV Infection$320,863
R41 · FY2025 · AI · contact PI
Safety and Efficacy Testing of FX101 in an SIV/NHP Model$637,692
R44 · FY2018 · MH · contact PI
Safety and Efficacy Testing of FX101 in an SIV/NHP Model$1,154,643
R44 · FY2017 · MH · contact PI
Standardizable Whole Blood Culture for Evaluating HIV Eradication Strategies$416,402
R43 · FY2016 · AI · contact PI
FIV Testing of a CNS-Relevant Antiretroviral Compound$345,048
R43 · FY2013 · MH · contact PI
FIV Testing of a CNS-Relevant Antiretroviral Compound$344,519
R43 · FY2012 · MH · contact PI
A Novel CNS-Penetrable Antiretroviral$248,052
R43 · FY2011 · MH · contact PI
A Novel CNS-Penetrable Antiretroviral$249,976
R43 · FY2010 · MH · contact PI